Chloroquine-resistant Plasmodium vivax in Papua New Guinea.

Abstract

An Australian expatriate on regular weekly antimalarial prophylaxis with chloroquine base and Maloprim developed symptomatic Plasmodium vivax infection which failed to respond adequately to 600 mg of chloroquine base. More ominously, a resident of the Highlands region of Papua New Guinea contracted vivax malaria which failed to be cleared by 2400 mg chloroquine base administered over 4 d. Both patients had achieved appropriate blood and plasma concentrations of chloroquine after treatment. Chloroquine-resistant P. vivax is now a clinical fact in Papua New Guinea.

• Authors: G J Schuurkamp, P E Spicer, R K Kereu, P K Bulungol, K H Rieckmann
• Journal: Transactions of the Royal Society of Tropical Medicine and Hygiene (Trans R Soc Trop Med Hyg) 1992 Mar-Apr Vol. 86 Issue 2 Pg. 121-2 ISSN: 0035-9203 [Print] England
• PMID: 1440763 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antimalarials
• Drug Combinations
• fanasil, pyrimethamine drug combination
• Maloprim
• Sulfadoxine
• Chloroquine
• Dapsone
• Pyrimethamine

Topics

• Animals
• Antimalarials (therapeutic use)
• Chloroquine (therapeutic use)
• Dapsone (therapeutic use)
• Drug Combinations
• Drug Resistance
• Humans
• Malaria, Vivax (drug therapy)
• Male
• Papua New Guinea
• Plasmodium vivax (drug effects)
• Pyrimethamine (therapeutic use)
• Sulfadoxine (therapeutic use)